EUCTR2013-004418-17-NO进行中（未招募）1 期
Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological rationale for the optimal selection of treatment regimens.
Oslo University Hospital0 个研究点开始时间: 2014年2月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Cohort I: Patients with large (radiologic measureable tumor > 2.0 cm) HER2 negative mammary carcinomas in the following categories are eligible for inclusion into the study:
- •T2 tumors with:
- •o Ki67 labeling index = 20%
- •oER positive and Progesterone receptor negative status
- •ograde 3 tumors
- •T3-T4 tumors with Ki67 = 15%.
- •The patients should not have received previous treatment for the current disease and should be without signs of metastatic disease as determined by liver ultrasound or CT scan and bone scintigraphy or MRI.
- •Cohort II: Patients with evaluable metastatic disease from breast carcinoma according to the RECIST criteria, AND elegible for biopsy of the metastatic tumor for diagnosis and research purposes before, during and after therapy.
- •1. Written informed consent obtained prior to any study-specific procedure
- •2. Female or male age ?18 years
- •3. Able to comply with the protocol
- •4. Histologically or cytologically confirmed, HER2-negative, men or women with breast
- •adenocarcinoma
- •5. WHO performance status = 2
- •6. Adequate hematological function
- •Absolute neutrophil count (ANC) =1.0 x 109/L
- •Platelet count =100 x 109/L
- •Hemoglobin = 10 g/dL (may be transfused to maintain or exceed this level)
- •7. Adequate liver function
- •Total bilirubin <1.5 x upper limit of normal (ULN)
- •AST, ALT <2.5 x ULN (in cohort I)
- •AST, ALT <5 x ULN (in cohort II)
- •8. Adequate renal function
- •Serum creatinine =1.25 x ULN or calculated creatinine clearance =50 mL/min
- •9. Normal baseline cardiac function (LVEF) as measured by MUGA or ECHO
- •10. Women should not be pregnant or breast-feeding. Women with an intact uterus
- •(unless amenorrhoeic for the last 24 months and premenopausal levels of FSH, LH
- •and oestradiol) must have a negative serum pregnancy test within 28 days prior to
- •inclusion into the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1. Previous chemotherapy treatment for localized breast cancer less than 24 months before inclusion into study (cohort I) or metastatic breast cancer treated with taxane (cohort II).
- •2. Other earlier or concomitant carcinoma less than five years prior to the breast cancer diagnosis, except for BCC, in situ cervix cancer or breast cancer
- •3. Clinically significant (i.e. active) cardiovascular disease for example CVA (=6 months before enrolment), myocardial infarction (=6 months before enrolment), unstable angina, congestive heart failure (CHF) NYHA Class =II, serious cardiac arrhythmia requiring medication during the study, which might interfere with regularity of the study treatment, or not controlled by medication
- •4. Treatment with any other investigational agent, or participation in another clinical intervention trial within 21 days prior to enrolment
- •5.Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications.
研究者
相似试验
进行中（未招募）
2 期
Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic SettingBreast CancerNCT02546232Oslo University Hospital196
已完成
3 期
ANZ 02P2 / International Breast cancer Intervention Study: IBIS-II Bone Sub-ProtocolOsteoporosisACTRN12605000222640Australia and New Zealand Breast Cancer Trials Group1,000
已完成
3 期
ANZ 02P2 / International Breast cancer Intervention Study: IBIS-II DCISIncreased breast cancer riskCancer - BreastACTRN12605000282684Australia and New Zealand Breast Cancer Trials Group4,000
已完成
3 期
ANZ 02P2 / International Breast cancer Intervention Study: IBIS-II (Prevention)Increased breast cancer riskReproductive Health and Childbirth - Menstruation and menopauseCancer - BreastACTRN12605000216617Australia and New Zealand Breast Cancer Trials Group6,000
进行中（未招募）
1 期
International Breast Cancer Intervention Study II (DCIS). An international multi-centre trial of tamoxifen v anastrozole in post-menopausal women with ductal carcinoma in-situ. - IBIS-II (DCIS)Ductal carcinoma in situMedDRA version: 17.0 Level: LLT Classification code 10013806 Term: Ductal carcinoma in situ System Organ Class: 100000004864EUCTR2004-003992-35-GBQueen Mary University of London4,000